Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
Por:
Rawstron, AC, Bottcher, S, Letestu, R, Villamor, N, Fazi, C, Kartsios, H, de Tute, RM, Shingles, J, Ritgen, M, Moreno, C, Lin, K, Pettitt, AR, Kneba, M, Montserrat, E, Cymbalista, F, Hallek, M, Hillmen, P, Ghia, P
Publicada:
1 ene 2013
Resumen:
Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally harmonised four-colour (CLR) flow cytometry MRD assay is widely used but has limitations. The aim of this study was to improve MRD analysis by identifying situations where a less time-consuming CD19/CD5/kappa/lambda analysis would be sufficient for detecting residual CLL, and develop a six-CLR antibody panel that is more efficient for cases requiring full MRD analysis. In 784 samples from CLL patients after treatment, it was possible to determine CD19/CD5/kappa/lambda thresholds that identified cases with detectable MRD with 100% positive predictive value (PPV). However, CD19/CD5/kappa/lambda analysis was unsuitable for predicting iwCLL/NCI response status or identifying cases with no detectable MRD. For the latter cases requiring a full MRD assessment, a six-CLR assay was designed comprising CD19/CD5/CD20 with (1) CD3/CD38/CD79b and (2) CD81/CD22/CD43. There was good correlation between four-CLR and six-CLR panels in dilution studies and clinical samples, with 100% concordance for detection of residual disease at the 0.01% (10(-4)) level (n = 59) and good linearity even at the 0.001-0.01% (10(-5)-10(-4)) level. A six-CLR panel therefore provides equivalent results to the four-CLR panel but it requires fewer reagents, fewer cells and a much simpler analysis approach. Leukemia (2013) 27, 142-149; doi:10.1038/leu.2012.216
Filiaciones:
Rawstron, AC:
Leeds Teaching Hosp, St Jamess Inst Oncol, HMDS, Leeds LS1 3EX, W Yorkshire, England
Univ York, Epidemiol & Canc Stat Grp, York YO10 5DD, N Yorkshire, England
Bottcher, S:
Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany
Letestu, R:
Hop Avicenne, AP HP, Serv Hematol Biol, F-93009 Bobigny, France
Univ Paris Nord, PRES Sorbonne Paris Cite, UMR Inserm Adaptateurs Signalisat Hematol U978, UFR SMBH, Bobigny, France
Villamor, N:
Hosp Clin Barcelona, Unitat Hematopatol, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Fazi, C:
Univ Vita Salute San Raffaele, Div Mol Oncol, Lab Cell Neoplasia B, Milan, Italy
Univ Vita Salute San Raffaele, Div Mol Oncol, Unit Lymphoid Malignancies, Milan, Italy
Univ Vita Salute San Raffaele, Dept Oncohematol, Milan, Italy
Univ Milan, Osped San Raffaele, I-20127 Milan, Italy
Kartsios, H:
Leeds Teaching Hosp, St Jamess Inst Oncol, HMDS, Leeds LS1 3EX, W Yorkshire, England
de Tute, RM:
Leeds Teaching Hosp, St Jamess Inst Oncol, HMDS, Leeds LS1 3EX, W Yorkshire, England
Shingles, J:
Leeds Teaching Hosp, St Jamess Inst Oncol, HMDS, Leeds LS1 3EX, W Yorkshire, England
Ritgen, M:
Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany
Moreno, C:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Lin, K:
Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Hematol, Liverpool, Merseyside, England
Pettitt, AR:
Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Hematol, Liverpool, Merseyside, England
Kneba, M:
Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany
Montserrat, E:
Hosp Clin Barcelona, Unitat Hematopatol, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Cymbalista, F:
Hop Avicenne, AP HP, Serv Hematol Biol, F-93009 Bobigny, France
Univ Paris Nord, PRES Sorbonne Paris Cite, UMR Inserm Adaptateurs Signalisat Hematol U978, UFR SMBH, Bobigny, France
Hallek, M:
Univ Cologne, Innere Med Klin 1, D-50931 Cologne, Germany
Hillmen, P:
Leeds Teaching Hosp, St Jamess Inst Oncol, Dept Clin Haematol, Leeds, W Yorkshire, England
Ghia, P:
Univ Vita Salute San Raffaele, Div Mol Oncol, Lab Cell Neoplasia B, Milan, Italy
Univ Vita Salute San Raffaele, Div Mol Oncol, Unit Lymphoid Malignancies, Milan, Italy
Univ Vita Salute San Raffaele, Dept Oncohematol, Milan, Italy
Univ Milan, Osped San Raffaele, I-20127 Milan, Italy
Bronze
|